Mahadevia Ankit
SEC CIK 1720974 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SPRO | Spero Therapeutics, Inc. | Dir | 703.3K | — | $312.6K | 14 | 2021-08-26 | 2025-08-28 |
Most active insiders at SPRO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Rajavelu Esther | See Remarks | — | $406.8K |
| 2 | Keutzer Timothy | COO | — | $145.2K |
| 3 | Tregoning Kathleen | Dir | — | — |
| 4 | Zack Debra | Chief Medical Off | — | — |
| 5 | Smith Cynthia | Dir | — | — |
| 6 | Jackson Scott Thomas | Dir | — | — |
| 7 | VINK PATRICK V.J.J. | Dir | — | — |
| 8 | Deshpande Milind | Dir | — | — |
| 9 | Pottage John C Jr | Dir | — | — |
| 10 | THOMAS FRANK E | Dir | — | — |
Mahadevia Ankit made no open-market trades at SPRO in the last 12 months.
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-03 | 2025-08-28 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | Dir | S - Sale | $1.97 | -6,572 | 703.3K | -0.9% | -$12.9K | |
| 2025-06-16 | 2025-06-12 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | Dir | A - Grant | $0.00 | +20.0K | 709.9K | +3% | $0 | |
| M | 2025-02-05 | 2025-02-05 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | Dir | S - Sale | $0.78 | -69.2K | 689.9K | -9% | -$54.0K |
| 2024-08-29 | 2024-08-27 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | Dir | S - Sale | $1.35 | -5,912 | 759.1K | -0.8% | -$7,981 | |
| 2024-05-30 | 2024-05-29 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | Dir | A - Grant | $0.00 | +20.0K | 765.0K | +3% | $0 | |
| 2024-02-05 | 2024-02-02 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | Dir | S - Sale | $1.37 | -63.8K | 745.0K | -8% | -$87.4K | |
| 2023-10-10 | 2023-10-05 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | Dir | A - Grant | $0.00 | +20.0K | 808.8K | +3% | $0 | |
| 2023-08-30 | 2023-08-28 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | Dir | S - Sale | $1.26 | -9,040 | 788.8K | -1% | -$11.4K | |
| 2023-02-06 | 2023-02-03 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | CEO, Pres, Dir | S - Sale | $1.81 | -12.3K | 797.8K | -2% | -$22.2K | |
| 2023-02-03 | 2023-02-01 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | CEO, Pres, Dir | A - Grant | $0.00 | +531.9K | 810.1K | +191% | $0 | |
| D | 2022-02-03 | 2022-02-01 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | CEO, Pres, Dir | A - Grant | $0.00 | +134.2K | 278.2K | +93% | $0 |
| D | 2021-12-29 | 2021-12-27 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | CEO, Pres, Dir | S - Sale+OE | $14.58 | -8,000 | 144.0K | -5% | -$116.6K |
| D | 2021-12-29 | 2021-12-27 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | CEO, Pres, Dir | M - OptEx | $5.90 | +8,000 | 152.0K | +6% | +$47.2K |
| 2021-08-30 | 2021-08-26 | SPRO | Spero Therapeutics, Inc. | Mahadevia Ankit | CEO, Pres, Dir | A - Grant | $0.00 | +78.2K | 144.0K | +119% | $0 |
Purchase Sale Sale after option exercise All abbreviations